Skip to main content

Table 2 Comparative analysis of gene expression changes in primary and metastatic melanoma.

From: The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis

Gene Symbol

Relative increase in gene expression

Gene Symbol

Relative decrease in gene expression

 

MIS to Thin

Thin To IM

IM to Thick

Thick to Met

MIS to Met

 

MIS to Thin

Thin To IM

IM to Thick

Thick to Met

MIS to Met

MAGEA2

<2

8.6

9.4

3.1

30.7

SPRR1A

<2

<2

<2

129.4

239.3

MAGEA3

<2

8.1

10.7

3

83.8

SPRR1B

<2

<2

<2

52.8

100.8

MAGE A6

<2

7.1

9.8

2.7

103

KRT16

<2

<2

<2

68.3

195.5

MAGEA1,2

<2

2.5

8.9

2.6

81.5

KRT17

<2

2.6

<2

27.4

57.6

MAGE A1

<2

<2

11.1

<2

25.4

KRT6B

<2

<2

<2

39.7

100.9

MAGE A5

<2

2.2

3.9

<2

11.7

AQP3

<2

<2

3.2

6.1

43.2

MMP19

5.4

<2

<2

<2

7.4

CD24

<2

<2

2

4.4

18.7

PDGFRL

22.3

3.6

<2

<2

6.3

FLG

<2

<2

3

24.1

140

C16orf34

5.4

<2

<2

<2

18.5

IVL

<2

2.2

<2

13.9

84.1

CTH

3.9

<2

<2

<2

8.8

KLK7

<2

<2

6.5

8.9

128

GPR19

4.2

<2

3

<2

23.9

LGALS7

<2

<2

3.4

17.3

109.3

SPP1

<2

13.1

<2

<2

44.9

LOR

<2

<2

2.4

22.6

120.4

HOXA10

<2

3.3

<2

<2

3.8

RAB25

<2

<2

3.3

10.3

88.4

MMP14

<2

3.6

<2

2.1

9

SFN

<2

<2

<2

10.6

24.2

AKT3

<2

<2

7.5

<2

14.3

C19orf33

3.1

<2

4.6

13.3

220.3

BCL2A1

<2

2.2

4.8

<2

18.7

ASAH3

<2

<2

25.9

<2

60

BIRC5

<2

<2

3.7

<2

3.4

KRT15

<2

<2

27.1

2.2

104.9

BUB1

<2

<2

9.4

<2

10.8

ELOVL4

<2

2.3

14.7

<2

41.9

CDC45L

<2

<2

13

<2

9.1

GATA3

2.5

<2

14.3

<2

23.5

CDK2

<2

<2

4.8

<2

8.4

MUC15

<2

2.2

11.9

<2

25

CSAG2

<2

<2

19.6

2.6

54.5

SCEL

<2

<2

28.8

<2

71.8

DUSP4

2

<2

5.7

<2

12.5

TP73L

<2

<2

5.5

3.4

41.2

DUSP6

<2

<2

3.7

<2

10.5

RORA

<2

<2

6.2

2.2

26.6

GYPC

<2

<2

12.2

<2

14.2

POU2F3

<2

<2

13.9

2.2

73.9

HEY1

<2

<2

5.7

<2

9.3

ICEBERG

<2

2.7

6.7

4.5

32.3

KIFC1

<2

<2

10.4

<2

16

CASZ1

<2

4.8

2.8

<2

12.3

PEG10

<2

2.4

4.1

<2

11.3

HR

<2

3.7

<2

<2

7.7

RASGRF1

<2

<2

5.1

<2

9.9

TMPRSS4

8.7

<2

<2

3.1

42

RGS20

3.4

<2

9.2

<2

34.3

STAR

4.9

<2

<2

<2

11.1

SLC16A4

<2

<2

4.4

<2

26.4

ST7L

4.3

<2

3.6

<2

8.4

SOX5

<2

<2

12.3

<2

19.8

LTB4R

4

<2

2.3

<2

9.9

TRIM51

<2

3.1

15.9

<2

63.6

HAS3

4.9

<2

<2

2.5

16.6

TYMS

<2

<2

3.6

<2

4.7

FGFR3

3.9

<2

3.2

<2

7.6

  1. NOTE: All annotated genes listed above with a < 2 indicates that any difference between tumors for each comparative analysis was less than 2-fold. Underlined numbers indicate the greatest change in gene expression across varying PCM tumor thickness for each gene. Abbreviations: MIS, melanoma-in-situ, Thin, thin melanomas < 1.0 mm in Breslow's thickness, I.M., intermediate thickness between 1–4 mm, with thick melanomas > 4 mm. PCM, primary cutaneous melanoma.
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us